Media Releases and Presentations
Ondek’s product ImmBALANCE® is being developed to reduce allergy in children and potentially prevent allergic disease in later life.
Sophisticated investors back Australian Nobel Laureate’s work on gut bacteria to develop new treatment for childhood allergy
Perth, Australia 27 June 2017
Ondek, the Australian biotechnology company founded by Nobel Laureate Professor Barry Marshall, today announced it raised A$3.59 million in equity funding from professional and high-net-worth investors.
Ondek® Awarded $920,000 for Clinical Study of Allergy Product
24 February 2014
Australian biotechnology company Ondek Pty Ltd today announced it has been awarded an NH&MRC Development Grant of $919,596 to subsidise a clinical trial on its first allergy product. The trial will be conducted with its clinical partners, Professor Susan Prescott and Professor Peter Richmond, Princess Margaret Hospital for Children in Perth, and Professor Kate Allen, The Royal Children’s Hospital in Melbourne.
Biotechnology Business Leader Appointed CEO of Australian Nobel Prize Winner’s Company
18 March 2013
Australian drug delivery system company Ondek Limited today announced the appointment of Dr Jenny Harry as Chief Executive Officer..